Oxra-L (Dapagliflozin/Linagliptin)

Product Overview

Oxra-L is a prescription combination tablet that delivers 10 mg of dapagliflozin and 5 mg of linagliptin in each dose. Produced by Sun Pharmaceutical Industries Ltd, the product is specifically formulated for the treatment of type 2 diabetes mellitus in adults whose glycemic control cannot be achieved with diet and exercise alone. The fixed‑dose design simplifies regimens by delivering both an SGLT‑2 inhibitor and a DPP‑4 inhibitor in a single daily tablet, which can improve adherence and reduce the pill burden compared with separate formulations. Oxra-L is indicated as an adjunct to lifestyle modifications and should be used in conjunction with appropriate dietary and physical activity measures to achieve optimal blood glucose levels.

What is Oxra-L?

Oxra-L belongs to a class of dual‑action antidiabetic agents that simultaneously target glucose reabsorption in the kidney and enhance incretin hormone activity in the pancreas. Dapagliflozin, an SGLT‑2 inhibitor, blocks the SGLT‑2 transporter on the proximal renal tubule, resulting in increased urinary excretion of glucose. Linagliptin, a DPP‑4 inhibitor, prevents the degradation of incretin peptides such as GLP‑1 and GIP, thereby amplifying glucose‑dependent insulin secretion and suppressing glucagon release. The synergy of these mechanisms provides a comprehensive approach to lowering fasting and post‑prandial glucose concentrations while minimizing the risk of hypoglycemia when used as monotherapy.

Uses and Benefits

Oxra-L is prescribed to improve glycemic control in patients with type 2 diabetes and to reduce the risk of cardiovascular complications associated with the disease. Clinical trials have demonstrated that the combination therapy yields greater reductions in HbA1c compared with either component administered alone, and it also contributes to modest weight loss and blood pressure reduction. In addition, real‑world studies suggest that patients on Oxra-L experience fewer episodes of hyperglycemia and have a lower incidence of glucose excursions, which translates into better overall metabolic stability. The medication may also be beneficial for patients with comorbidities such as hypertension or dyslipidemia, as it can positively influence these parameters when combined with appropriate therapeutic strategies.

How It Works

The pharmacodynamic profile of Oxra-L is characterized by a dual mechanism of action. Dapagliflozin inhibits the SGLT‑2 transporter, leading to an approximate 60 % increase in renal glucose excretion independent of insulin levels. This results in lowered plasma glucose concentrations and a reduction in renal workload. Linagliptin, by contrast, binds reversibly to the DPP‑4 enzyme, preserving the activity of incretin hormones that stimulate insulin release in a glucose‑dependent manner. The combined effect produces a synergistic lowering of both fasting and post‑prandial glucose without causing excessive insulin secretion, thereby maintaining a low hypoglycemia risk profile. Additional indirect benefits include improved endothelial function and modest anti‑inflammatory effects observed in cardiovascular outcome studies.

Dosage Guidelines

Oxra-L is administered orally at a standard dose of one tablet daily, preferably at the same time each day, with or without food. The dosage is not weight‑based; however, patients with moderate to severe renal impairment (estimated glomerular filtration rate [eGFR] 30–45 mL/min/1.73 m²) may require dose adjustment or close monitoring, as the elimination of dapagliflozin is renally mediated. If a dose is missed, the patient should take it as soon as remembered unless it is close to the time of the next scheduled dose, in which case the missed dose should be skipped and the regular dosing schedule resumed. Consistency in dosing helps maintain steady plasma concentrations and maximizes therapeutic efficacy. Routine laboratory monitoring of kidney function, liver enzymes, and glycemic control is recommended at intervals determined by the prescribing clinician.

Side Effects

Most adverse reactions associated with Oxra-L are mild to moderate and include genital mycotic infections, urinary tract infections, and nasopharyngitis. These events are typically self‑limiting and respond well to appropriate hygiene and, when necessary, antifungal or antibacterial therapy. Less common but clinically important side effects comprise ketoacidosis, severe renal dysfunction, and acute pancreatitis; patients should be advised to seek immediate medical attention if they develop persistent nausea, vomiting, abdominal pain, or unexplained fatigue, which may signal metabolic disturbances. Additionally, rare hypersensitivity reactions such as rash or angioedema have been reported, warranting discontinuation of the medication and urgent medical evaluation.

Warnings and Precautions

Oxra-L is contraindicated in individuals with known hypersensitivity to dapagliflozin, linagliptin, or any component of the formulation, as well as in patients with type 1 diabetes, severe renal impairment (eGFR < 45 mL/min/1.73 m²), or a history of diabetic ketoacidosis. Caution is advised in patients with a history of pancreatitis, hepatic dysfunction, or conditions that may compromise renal perfusion, such as severe dehydration or recent surgery. Alcohol consumption should be moderate, as excessive intake can potentiate the risk of hypoglycemia and volume depletion. Patients should be instructed to maintain adequate hydration, particularly in hot weather or during circumstances that increase fluid loss, and to report any signs of infection or unusual bleeding promptly.

Patient Counseling and Lifestyle Recommendations

Patients prescribed Oxra-L should be advised to adopt a balanced diet low in refined carbohydrates and to engage in regular physical activity, as these measures synergize with the medication to achieve optimal glycemic control. It is important to monitor blood glucose levels periodically and to keep a log of any symptoms suggestive of hypoglycemia, although the risk is low when Oxra-L is used alone. Adequate hydration is essential; patients should aim for at least 1.5–2 liters of fluid intake daily, especially in hot climates or during vigorous exercise. For more detailed guidance on diabetes care, refer to the National Institutes of Health. Proper storage of the medication in a cool, dry place away from direct sunlight preserves tablet integrity; the strip should be kept sealed until use. In the event of a missed dose, the patient should take the tablet as soon as remembered unless it is within 12 hours of the next scheduled dose, in which case the missed dose should be skipped to maintain the once‑daily regimen. Finally, any new over‑the‑counter medications, supplements, or herbal products should be discussed with a healthcare professional to prevent potential drug interactions.

Frequently Asked Questions

1. What is the recommended starting dose of Oxra-L?

Oxra-L is generally initiated at the standard dose of one 10 mg/5 mg tablet daily. Dosage adjustments may be made by a healthcare professional based on renal function, glycemic response, and tolerance.

2. Can Oxra-L be used in patients with chronic kidney disease?

Oxra-L should be used with caution in patients with reduced kidney function. It is not recommended when eGFR falls below 45 mL/min/1.73 m² due to altered drug clearance.

3. Does Oxra-L cause weight loss?

Yes, clinical studies have shown modest weight reduction as a secondary benefit, attributed to the glucosuric effect of dapagliflozin and the appetite‑modulating properties of linagliptin.

4. How does Oxra-L affect cardiovascular risk?

Studies indicate that the combination therapy can reduce the incidence of major adverse cardiovascular events, particularly in patients with existing cardiovascular disease or multiple risk factors.

5. Is it safe to take Oxra-L with other diabetes medications?

Oxra-L can be combined with metformin, but it is not recommended to use it alongside other DPP‑4 inhibitors or SGLT‑2 inhibitors to avoid overlapping mechanisms and increased side‑effect burden.

For additional scientific details, refer to the U.S. Food and Drug Administration and the MedlinePlus resource library.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)